<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39345748</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1976-8257</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Toxicological research</Title><ISOAbbreviation>Toxicol Res</ISOAbbreviation></Journal><ArticleTitle>Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database.</ArticleTitle><Pagination><StartPage>673</StartPage><EndPage>682</EndPage><MedlinePgn>673-682</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s43188-024-00256-x</ELocationID><Abstract><AbstractText>The purpose of this study was to analyze the important medical events (IMEs) of anti-severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) monoclonal antibodies using the reports from the United States Food and Drug Administration (US FDA) adverse event reporting system (FAERS) and to detect safety signals. In this study, data from the FAERS from January 2020 to December 2022 were used to investigate signals associated with five monoclonal antibody products (bamlanivimab, bamlanivimab/etesevimab, bebtelovimab, casirivimab/imdevimab, sotrovimab) in coronavirus disease 2019 (COVID-19) patients and one monoclonal antibody product (tixagevimab/cilgavimab) in patients wherein COVID-19 vaccination was not recommended. Disproportionality analyses were conducted using the reporting odds ratio, and an information component to identify safety signals. There were 17,937,860 drug AE reports associated with all drugs in the FAERS documented during research period. Among them, 42,642 were AE reports associated with anti-SARS-CoV-2 monoclonal antibodies. The SOCs including respiratory, thoracic and mediastinal, and vascular disorders were frequently reported for all the six products. The three most commonly detected IMEs were hypoxia, COVID-19 pneumonia, and anaphylactic reaction due to SARS-CoV-2 neutralizing antibodies. Even though the purposes of use were different, the types of signals between drugs were similar. Careful monitoring of these AEs should be considered for certain COVID-19 patients, at risk, when they are treated with monoclonal antibody products.</AbstractText><CopyrightInformation>© The Author(s) under exclusive licence to Korean Society of Toxicology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Min Joung</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, 309 Pilmun-Daero, Dong-gu, Gwangju, 61452 Republic of Korea.</Affiliation><Identifier Source="ROR">https://ror.org/01zt9a375</Identifier><Identifier Source="GRID">grid.254187.d</Identifier><Identifier Source="ISNI">0000 0000 9475 8840</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Se-Hun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Bucheon-Si, Gyeonggi-do 14662 Republic of Korea.</Affiliation><Identifier Source="ROR">https://ror.org/01fpnj063</Identifier><Identifier Source="GRID">grid.411947.e</Identifier><Identifier Source="ISNI">0000 0004 0470 4224</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yun-Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Bucheon-Si, Gyeonggi-do 14662 Republic of Korea.</Affiliation><Identifier Source="ROR">https://ror.org/01fpnj063</Identifier><Identifier Source="GRID">grid.411947.e</Identifier><Identifier Source="ISNI">0000 0004 0470 4224</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ki</LastName><ForeName>Sung Hwan</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-0761-3750</Identifier><AffiliationInfo><Affiliation>Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chosun University, 309 Pilmun-Daero, Dong-gu, Gwangju, 61452 Republic of Korea.</Affiliation><Identifier Source="ROR">https://ror.org/01zt9a375</Identifier><Identifier Source="GRID">grid.254187.d</Identifier><Identifier Source="ISNI">0000 0000 9475 8840</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Toxicol Res</MedlineTA><NlmUniqueID>101483324</NlmUniqueID><ISSNLinking>1976-8257</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Emergency use authorization</Keyword><Keyword MajorTopicYN="N">FDA adverse event reporting system</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 neutralizing monoclonal antibody drugs</Keyword></KeywordList><CoiStatement>Conflict of interestSung Hwan Ki was the Associate Editor of Toxicological Research while the manuscript of this article was submitted and peer-reviewed. Editorial Board Member status has no bearing on editorial consideration.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39345748</ArticleId><ArticleId IdType="pmc">PMC11436521</ArticleId><ArticleId IdType="doi">10.1007/s43188-024-00256-x</ArticleId><ArticleId IdType="pii">256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FDA. Information about the covid 19 treatments. http://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. Accessed 31 Dec 2023</Citation></Reference><Reference><Citation>Jiang S, Hillyer C, Du L (2020) Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 41:355–359. 10.1016/j.it.2020.03.007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129017</ArticleId><ArticleId IdType="pubmed">32249063</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ (2022) Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19. N Engl J Med 386:2188–2200. 10.1056/NEJMoa2116620</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Administration US FDA Adverse event reporting system. http://open.fda.gov/data/fares. Accessed 31 Dec 2023</Citation></Reference><Reference><Citation>de Abajo FJ (2005) Improving pharmacovigilance beyond spontaneous reporting. Intern J Pharma Med 19:209–218. 10.2165/00124363-200519040-00002</Citation></Reference><Reference><Citation>Woo EJ (2014) Postmarketing safety of biologics and biological devices. Spine J 14:560–565. 10.1016/j.spinee.2013.09.056</Citation><ArticleIdList><ArticleId IdType="pubmed">24342704</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukazawa C, Hinomura Y, Kaneko M, Narukawa M (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 27:1402–1408. 10.1002/pds.4672</Citation><ArticleIdList><ArticleId IdType="pubmed">30324671</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109–117. 10.2165/00002018-199920020-00002</Citation><ArticleIdList><ArticleId IdType="pubmed">10082069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti M, Fusaroli M, Raschi E, Moretti U, Poluzzi E, De Ponti F (2021) Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert Opin Drug Saf 20:1421–1431. 10.1080/14740338.2021.1956461</Citation><ArticleIdList><ArticleId IdType="pubmed">34280062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, Poluzzi E (2022) Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol 25:727–736. 10.1093/ijnp/pyac031</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515127</ArticleId><ArticleId IdType="pubmed">35639870</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA. Agency EMA important medicinal event terms list version 25. http://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eurdavigilance/eudravigilance-system-overview. Accessed 31 Dec 2023</Citation></Reference><Reference><Citation>Baek J-W, Yang BR, Choi S, Shin K-H (2021) Signal Detection for adverse events of finasteride using Korea Adverse Event Reporting System (KAERS) database. Korean J Clin Pharm 31:324–331. 10.24304/kjcp.2021.31.4.324</Citation></Reference><Reference><Citation>Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796.10.7150/ijms.6048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689877</ArticleId><ArticleId IdType="pubmed">23794943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions. Drug Saf 29:385–396. 10.2165/00002018-200629050-00003</Citation><ArticleIdList><ArticleId IdType="pubmed">16689555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramírez E, González-Munoz M, Kulkarni C, de Abajo FJ (2022) Reducing the harm of medication-recent trends in pharmacovigilance. Front Pharmacol 13:964125. 10.3389/fphar.2023.1175039</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469192</ArticleId><ArticleId IdType="pubmed">36110529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G (2015) Utilizing social media data for pharmacovigilance: a review. J Biomed Inform 54:202–212. 10.1016/j.jbi.2015.02.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408239</ArticleId><ArticleId IdType="pubmed">25720841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Shu Y, Zhu J, Li F, Li J (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci Rep 12:19555. 10.1038/s41598-022-23834-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9664039</ArticleId><ArticleId IdType="pubmed">36380085</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA (2022) Fact sheet for healthcare providers: emergency use authorization for bamlanivimab. https://www.fda.gov/media/143603/download</Citation></Reference><Reference><Citation>FDA (2021) Fact sheet for healthcare providers: emergency use authorization of REGEN-COV (casirivimab and imdevimab). https://www.fda.gov/media/145611/download</Citation></Reference><Reference><Citation>FDA (2022) Fact sheet for healthcare providers: Emergency use authorization of bamlanivimab and etesevimab. https://www.fda.gov/media/145802/download</Citation></Reference><Reference><Citation>FDA (2022) Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. https://www.fda.gov/media/149534/download</Citation></Reference><Reference><Citation>FDA (2022) Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. https://www.fda.gov/media/156152/download</Citation></Reference><Reference><Citation>FDA (2023) Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). https://www.fda.gov/media/154701/download</Citation></Reference><Reference><Citation>EMA (2021) Regkirona. https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona</Citation></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H, Abbott A, Abbott A (2022) Baricitinib in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400:359–368. 10.1016/S0140-6736(22)01109-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A (2022) Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386:1397–1408. 10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML (2022) Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 386:509–520. 10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C, Kudchodkar SB, Chung CN, Park YK, Xu Z, Pardi N, Abdel-Mohsen M, Muthumani K (2023) Expanding the reach of monoclonal antibodies: a review of synthetic nucleic acid delivery in immunotherapy. Antibodies 12:46. 10.3390/antib12030046</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10366852</ArticleId><ArticleId IdType="pubmed">37489368</ArticleId></ArticleIdList></Reference><Reference><Citation>Renn A, Fu Y, Hu X, Hall MD, Simeonov A (2020) Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci 41:815–829. 10.1016/j.tips.2020.07.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572790</ArticleId><ArticleId IdType="pubmed">32829936</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti D, Purcell LA, Snell G, Veesler D (2021) Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184:3086–3108. 10.1016/j.cell.2021.05.005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8152891</ArticleId><ArticleId IdType="pubmed">34087172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SS, Parthasarathy K, Sounderrajan V, Neelagandan K, Anbazhagan P, Chandramouli V (2023) Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review. 3 Biotech 13:5. 10.1007/s13205-022-03416-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741861</ArticleId><ArticleId IdType="pubmed">36514483</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland W-H, Porrot F, Staropoli I, Lemoine F (2022) Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602:671–675. 10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina KC, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR (2023) Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA. 4/BA. 5. Int J Infect Dis 132:34–39. 10.1016/j.ijid.2023.04.396</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10106116</ArticleId><ArticleId IdType="pubmed">37072054</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips SP, Carver LF (2023) Greatest risk factor for death from covid-19: older age, chronic disease burden, or place of residence? descriptive analysis of population-level canadian data. Int J Environ Res Public Health 20:7181. 10.3390/ijerph20247181</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10742949</ArticleId><ArticleId IdType="pubmed">38131732</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw AJ, Oude Luttikhuis MA, Wellen AC, Müller C, Calkhoven CF (2021) Obesity and its impact on COVID-19. J Mol Med 99:899–915. 10.1007/s00109-021-02072-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023779</ArticleId><ArticleId IdType="pubmed">33824998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessie ZG, Zewotir T (2021) Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 21:855. 10.1186/s12879-021-06536-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380115</ArticleId><ArticleId IdType="pubmed">34418980</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaassen Z, Wallis CJ (2021) Assessing patient risk from cancer and COVID-19: managing patient distress. Urol Oncol 39:243–246. 10.1016/j.urolonc.2021.01.023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834973</ArticleId><ArticleId IdType="pubmed">33558139</ArticleId></ArticleIdList></Reference><Reference><Citation>Purohit D, Ahirwar AK, Sakarde A, Asia P, Gopal N (2021) COVID-19 and lung pathologies. Horm Mol Biol Clin Invest 42:435–443. 10.1515/hmbci-2020-0096</Citation><ArticleIdList><ArticleId IdType="pubmed">34333882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Chi J, Lv W, Wang Y (2021) Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 37:e3377. 10.1002/dmrr.3377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361201</ArticleId><ArticleId IdType="pubmed">32588943</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena P, Muthu J (2023) COVID-19 and sickle cell disease: two independent risk factors for venous thromboembolism. Cureus 15:e37226. 10.7759/cureus.37226</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10163976</ArticleId><ArticleId IdType="pubmed">37159776</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Liu Y, Cheng Z, Yu X, Li Y (2022) COVID-19-associated liver injury: clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacotherap 154:113568. 10.1016/j.biopha.2022.113568</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381432</ArticleId><ArticleId IdType="pubmed">36029543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C (2020) Mild or moderate Covid-19. N Engl J Med 383:1757–1766. 10.1056/NEJMcp2009249</Citation><ArticleIdList><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Kim J, Lee KH, Lee JA, Kim CH, Lee SH, Park BJ, Kim JH, Ahn JY, Jeong SJ (2023) Risk factors of pneumothorax and pneumomediastinum in COVID-19: a matched case–control study. BMC Infect Dis 23:137. 10.1186/s12879-023-08104-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9990560</ArticleId><ArticleId IdType="pubmed">36882735</ArticleId></ArticleIdList></Reference><Reference><Citation>Berenguer J (2022) Neutralizing antibodies for SARS-CoV-2 infection. Rev Esp Quimioter 35:16. 10.37201/req/s03.04.2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9717458</ArticleId><ArticleId IdType="pubmed">36285851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Xiaonan T (2021) Comparison of COVID-19 and influenza characteristics. J Zhejiang Univ Sci B 22:87. 10.1631/jzus.B2000479</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7885750</ArticleId><ArticleId IdType="pubmed">33615750</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH (2022) Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc 11:177–185. 10.1093/jpids/piab124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903349</ArticleId><ArticleId IdType="pubmed">35107571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V, Syrigou R-E, Theodorakakou F, Fotiou D, Migkou M (2023) Tixagevimab/Cilgavimab as pre-exposure prophylaxis against covid-19 for multiple myeloma patients: a prospective study in the omicron era. Diseases 11:123. 10.3390/diseases11030123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10529256</ArticleId><ArticleId IdType="pubmed">37754319</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SL, Buckley BJ, Rivera-Caravaca JM, Zhang J, Lip GY (2021) Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. Eur Heart J Qual Care Clin Outcomes 7:330–339. 10.1093/ehjqcco/qcab029</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294691</ArticleId><ArticleId IdType="pubmed">34107535</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CA (2022) Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 28:410–422. 10.1038/s41591-021-01630-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar MA, Shakkour Z, Reslan MA, Al-Haj N, Chamoun P, Habashy K, Kaafarani H, Shahjouei S, Farran SH, Shaito A (2022) SARS-CoV-2 involvement in central nervous system tissue damage. Neural Regen Res 17:1228. 10.4103/1673-5374.327323</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643043</ArticleId><ArticleId IdType="pubmed">34782556</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S-Y, Choi M, Cheong C, Ryoo S, Huh K, Yoon YK, Choi J, Kim SB (2023) Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: a living systematic review and meta-analysis. J Microbiol Immunol Infect 56:909–920. 10.1016/j.jmii.2023.07.009</Citation><ArticleIdList><ArticleId IdType="pubmed">37598054</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnovale C, Mazhar F, Pozzi M, Gentili M, Clementi E, Radice S (2018) A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database. Expert Opin Drug Saf 17:1161–1169. 10.1080/14740338.2018.1550069</Citation><ArticleIdList><ArticleId IdType="pubmed">30451017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>